A Mount Sinai study reported that BCMA-directed CAR-T cells can linger in the gut and correlate with severe intestinal inflammation in a subset of patients. The finding ties therapy persistence in the gastrointestinal tract to inflammatory risk, adding a new clinical monitoring dimension for CAR-T patients beyond systemic toxicity assessment.